Ann: US grants fund PAT-DX1 and PAT-DX1-NP targeting brain tumors, page-30

Multi Billion US dollar valuation opportunity. Current value around US$11m.

https://biopharmadealmakers.nature.com/users/177838-patrys/posts/39149-nuclear-penetrating-dna-binding-antibodies-as-cancer-therapies

Antibodies have been used as anticancer drugs for more than 20 years and have revolutionized cancer therapy with their ability to bind to specific targets. Most conventional antibodies cannot enter cells, and thus can only target markers on the cell surface, resulting in a wide range of inaccessible intracellular targets. In addition, few cell-surface markers are completely cancer-specific, leading to side effects when antibodies attack healthy cells.

Patrys, a Melbourne-based biotech company, is overcoming these limitations by developing cell- penetrating antibodies (Deoxymabs), a completely new antibody-based technology that targets tumors, penetrates cells, binds to DNA and blocks DNA repair.